Batavia Biosciences releases ‘Amalia,’ a novel manufacturing facility in Leiden, The Netherlands, enhancing their capability in viral vaccine and vector production.
Batavia Biosciences has announced the launch of ‘Amalia,’ a new GMP-ready manufacturing facility in Bilthoven, Netherlands.
This facility marks a significant advancement in the company’s ability to produce viral vaccines and viral vectors for clinical manufacturing. Menzo Havenga, CEO of Batavia Biosciences, highlights that Amalia aligns with the company’s mission to bring medical solutions from the lab to patients, especially in the context of epidemic preparedness.
The facility, equipped with advanced technology and adhering to high-quality standards, is set to play a crucial role in vaccine and viral vector development and production.
Amalia is part of Batavia Biosciences’ broader expansion strategy, with further developments anticipated, including a larger facility in Leiden.
For more details and future updates from Batavia Biosciences, please refer to their official announcements.
This strategic move allows us to better integrate into this unique community, empowering us to strengthen collaborations with leading researchers and provide exceptional, on-site support to our partners in life science research and pharmaceutical development.
On Tuesday 16 December, Leiden University Medical Center welcomed His Majesty King Willem-Alexander and Minister Jan Anthonie Bruijn of the Ministry of Health, Welfare and Sport...
Vanmiddag nam minister Jan Anthonie Bruijn van het ministerie van Volksgezondheid, Welzijn en Sport in Leiden, bij het LUMC, het rapport ‘Nederland in de voorhoede: rode biotech...